

## Special Issue

# Pharmacological Treatment for Gout

### Message from the Guest Editors

Gout is the most common form of inflammatory arthritis in men and has a prevalence of 1–4% globally. The incidence of gout is rising worldwide, including in both developing and, more dramatically, in developed nations. Gout is caused by the deposition of urate crystals. Treatment for acute gout flares focuses on alleviating the pain due to the intense inflammation and includes short courses of nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine or glucocorticosteroids. Treatment of chronic gout centres on preventing gout flares and promoting the dissolution of tophi (urate deposits, if present) with urate-lowering therapy (ULT). Despite the availability of effective and generally tolerable preventative treatments for gout, inadequate dosages and poor rates of persistence with ULT treatment regimens are prominent barriers to successful management. Authors are invited to submit their quantitative and qualitative research contributing to the understanding of the current state of gout treatment. The proposed topics cover factors contributing to a suboptimal response to gout treatment, novel approaches to treating gout and interventions to improve gout management.

### Guest Editors

Dr. Sophie Stocker

School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia

Dr. Daniel F. B. Wright

School of Pharmacy, University of Otago, P.O. Box 56, Dunedin 9056, New Zealand

### Deadline for manuscript submissions

closed (31 January 2024)



## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/143287](https://mdpi.com/si/143287)

*Pharmaceuticals*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)

[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





# Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



## About the Journal

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

---

### Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)